MannKind Reports Positive Phase 3 Data of AFREZZA in Patients with Type 2 Diabetes

MannKind Corporation

today announced positive preliminary results from Study 175, a Phase 3 clinical study of AFREZZA® (insulin human [rDNA origin]) Inhalation Powder, an investigational, ultra rapid-acting mealtime insulin therapy administered using MannKind's next-generation (Gen2) inhaler (also known as the Dreamboat™ inhaler), in patients with type 2 diabetes. Highlights AFREZZA combined with oral therapy, compared to oral therapy alone, showed: Superior reductions in A1c levels; Significantly more patients reached A1c target levels;